COVID-19 and Anticoagulants

19 December 2022

Recent evidence shows potentially significant drug interactions may occur between COVID-19 treatments, including Paxlovid, Lagevrio and Veklury and anticoagulants. Broadly speaking:

Lagevrio – there are no reported significant drug interactions with anticoagulants, particularly with Direct Oral Anticoagulants (DOACs) at this time.

Paxlovid – there are important interactions with anticoagulants, particularly with DOACs and also with warfarin.

Veklury – may increase or decrease the anticoagulant effect of warfarin.  Such interactions can impact on laboratory monitoring of anticoagulant use and the safe use of anticoagulants. 

It is advised that drug interactions are checked if patients are commenced on the above-listed COVID-19 treatments. Refer to the product information sheets; additionally, the following links provide information on potentially significant drug interactions: 

It is recommended that you consult with a pharmacist as well as the appropriate clinical services if potentially significant drug interactions are identified.

General News

28
Feb

Rare Diseases Day 2022

Rare Disease Day took place on the 28th of February and aims...

28
Jan

New iPath offers improved access to pathology results

A recent upgrade to iPath, SA Pathology's web-based result d...

28
Jan

Newsletter Error

SA Pathology would like to acknowledge a system error that o...

28
Jan

Faecal Pancreatic Elastase testing

SA Pathology now performs Faecal Pancreatic Elastase Level t...

7
Jul

COVID-19 Domiciliary Services

SA Pathology offers a COVID-19 domiciliary service to all me...